secwatch.observer — SEC 8-K summary
======================================

Issuer:     Erasca, Inc. (ERAS)
CIK:        0001761918
Form:       8-K
Filed at:   2022-08-11T23:59:59+00:00
Accession:  0000950170-22-016874
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Erasca Q2 net loss $35.6M; cash $390.8M; pipeline on track for H2 catalysts
---------------------------------------------------------------------------

- Net loss of $35.6M ($0.30 per share) vs $28.2M ($1.20) year ago; R&D expenses $27.5M, G&A $8.4M.
- Cash, equivalents, and marketable securities $390.8M as of June 30, 2022; expected to fund operations into H2 2024.
- Initial Phase 1b monotherapy data for ERAS-007 (HERKULES-1) and Phase 1 data for ERAS-601 (FLAGSHP-1) expected H2 2022.
- IND filing for CNS-penetrant KRAS G12C inhibitor ERAS-3490 in KRAS G12C-mutant NSCLC expected H2 2022.
- Entered clinical trial collaboration with Eli Lilly to evaluate cetuximab + ERAS-601; expanded leadership and board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1761918/000095017022016874/0000950170-22-016874-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1761918/000095017022016874/eras-20220811.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-016874

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer